NCT05233397View on ClinicalTrials.gov

ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

PHASE2RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

December 16, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Adamantinomatous CraniopharyngiomaRecurrent Adamantinomatous Craniopharyngioma
Interventions
DRUG

Tocilizumab

For \< 30 kg: 12 mg/kg IV every 2 weeks; For ≥30 kg: 8 mg/kg IV every 2 weeks

Trial Locations (12)

2031

RECRUITING

Sydney Children's Hospital, Randwick

4101

RECRUITING

Queensland Children's Hospital, South Brisbane

6000

RECRUITING

Perth Children's Hospital, Perth

20010

RECRUITING

Children's National Medical Center, Washington D.C.

27710

RECRUITING

Duke Children's Hospital, Durham

33155

RECRUITING

Nicklaus Children's Hospital, Miami

43235

RECRUITING

Nationwide Children's Hospital, Columbus

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

77030

RECRUITING

Texas Children's Hospital, Houston

80045

RECRUITING

Children's Hospital Colorado, Aurora

98105

RECRUITING

Seattle Children's Hospital, Seattle

Unknown

RECRUITING

McGill University Health Center, Montreal

All Listed Sponsors
collaborator

Children's Hospital Colorado

OTHER

lead

Nationwide Children's Hospital

OTHER